obesity-995x60.png
FEATURED ARTICLES
Calidi's Study Aims To Have An Oncolytic Virus Outsmart The Immune System
Calidi’s Eric Poma, Ph.D., explains how CLD-401 could evade immune clearance — and how the biotech is designing Phase 1 to prove safety and efficacy fast.
-
![African American Businessman-GettyImages-497984466]( "With CROs, Decide What You Can Actually Manage")
With CROs, Decide What You Can Actually ManageIndustry veteran Peter Fredette explores how small biotechs can rethink CRO outsourcing by balancing cost, operational needs, and internal oversight. Before choosing a CRO model, sponsors must honestly assess which services they need — and how many partners they can realistically manage.
-
![nurse-smiling-Getty 2201087559]( "When Vendor Disruption Threatens Trial Timelines: What Sponsors Should Do Next")
When Vendor Disruption Threatens Trial Timelines: What Sponsors Should Do NextWhen vendors face disruptions, trials can be affected. Discover key questions to assess partner stability, strengthen operational resilience, and keep studies on track.
-
![Healthcare, Medical service, Health insurance-GettyImages-2191629470]( "How Plain Language Summaries Created Under EU CTR Can Help Shape NIH Policy")
How Plain Language Summaries Created Under EU CTR Can Help Shape NIH PolicyAs the NIH shapes its plain language summary policy, EU CTR experience offers practical lessons on clarity, privacy, consistency, and implementation.
SERVICES AND PRODUCTS
Explore the breadth of Altasciences’ expertise in clinical pharmacology studies, supporting regulatory submissions across a diverse range of therapeutic areas.
Managing clinical trial disclosure can be challenging with the ever-evolving regulatory landscape, and varying requirements across different jurisdictions and regulatory bodies. New and updated regulations need to be continuously monitored and assessed for potential impact on an organization, processes and overall strategy.
Ypsomed accelerates clinical progress by reducing barriers across clinical development, enabling earlier study readiness, greater visibility and more informed decisions.
Explore validated pain models and integrated early-phase services designed to characterize dose response, evaluate safety and efficacy, and support informed decisions in analgesic development.
DECODE, the Digital Endpoint Collaboration for Outcomes Development, is Ametris’ pre-competitive collaboration framework designed to help address shared clinical measurement challenges across the life sciences industry. In regulatory contexts where evidence expectations are high, digital measures must be meaningful to patients, scientifically valid, operationally feasible, and aligned with regulatory expectations. By supporting the development and validation of fit-for-purpose, patient-centered digital measures, DECODE helps transform real-world data into validated clinical evidence across clinical research programs.